Synta Pharmaceuticals Corp.
Late last year, Clovis Oncology (NASDAQ: CLVS) saw its share price cut in half, to $11.50, after reporting that its Phase 3 drug CO-101 failed to show a benefit over chemotherapy. The company said it was shutting down the development of the trial and was going to focus on its pipeline.
Now, Clovis Oncology is trading near $73 with gains of more than 100%. The gains followed exceptional data more »
Biotechnology stocks offer investors some of the highest potential for returns of any industry. However, these stocks also come with incredible risk that can cause share prices to rise and fall because of binary events. This is especially true for small-cap biotech stocks, particularly in the cancer space. One biotech stock that appears to be a future winner is Synta Pharmaceuticals (NASDAQ: SNTA).
Synta Pharmaceuticals is a development stage biotechnology more »
Biopharmaceutical stocks can be extremely volatile and exciting. Certain catalysts that move these stocks can be impossible to predict, and hype and speculation will often run rampant. I would like to give an overview of the four most interesting biotech stocks that have come to my attention this week, listed below:
- Sinovac Biotech (SVA)
- Arca Biopharma (ABIO)
- Synta Pharmaceuticals (SNTA)
- Navidea Biopharmaceuticals (NAVB)
All these stocks have the potential to more »
It was an exciting end to what was a boring week. The weak SELL signal that our portfolio was under switched to a NEUTRAL signal on Friday morning with the Nasdaq gapping above the 50 day moving average. This automatically put us at NEUTRAL as the 50 day moving average was the fail safe area. In the final 30 minutes of trading the stock market indexes began to take off more »